Toxicity Liabilities Screening

Toxicity Liabilities Screening is a computational or experimental assessment method that identifies potential adverse biological effects of candidate drug molecules by systematically evaluating their structural and physicochemical properties against known toxicity markers to prioritize safer compounds in early drug discovery.

8

Publications

599

Citations

48

Authors

17

Institutions

Publications per year

2017–2026

3

Authors

48

  1. TY
    Tony Y. Zhang

    Eli Lilly (United States), United States

    1 publications · 13 citations

    1

    h-index

  2. CH
    Catrin Hasselgren

    Pfizer (United States), United States

    1 publications · 40 citations

    1

    h-index

  3. SB
    Scott Boyer

    AstraZeneca (Sweden), Sweden

    1 publications · 40 citations

    1

    h-index

  4. NT
    Nick Thomas

    Whitchurch Hospital, United Kingdom

    1 publications · 155 citations

    1

    h-index

  5. YW
    Yvonne Will

    Pfizer (United States), United States

    1 publications · 158 citations

    1

    h-index

1–5 of 48

Venues

  1. Toxicological Sciences

    2 publications · 313 citations

    2

    h-index

  2. 1

    h-index

  3. MedChemComm

    1 publications · 40 citations

    1

    h-index

  4. Journal of Cheminformatics

    1 publications · 15 citations

    1

    h-index

  5. bioRxiv (Cold Spring Harbor Laboratory)

    Repository · 1 publications · 13 citations

    1

    h-index

1–5